DALLAS, July 10,
2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a
late-stage clinical biotechnology company developing gene therapies
for inherited retinal diseases and age-related macular
degenerations (AMD), today announced that its Multi-Characteristic
Opsin (MCO) gene therapy platform will be featured in a
presentation by Dr. Michael Singer,
Clinical Professor of Ophthalmology at the University of Texas Health Science Center, at
the 2024 ASRS Annual Scientific Meeting taking place from
July 17-July 20, 2024 at the
Stockholmsmässan Convention Center in Stockholm, Sweden.
Details for the presentation are as follows:
Abstract Title: BCVA analysis of low- or high-dose
MCO-010 mutation agnostic optogenetic therapy for retinitis
pigmentosa: FIRST TIME 100-week TOPLINE Results from a Phase
2b/3 Randomized Sham-Controlled
Clinical Trial (RESTORE)
Session Type: Late-Breaking Symposium Presentation
Session Title: Symposium 3: Hereditary Retinal Disease &
Genetics
Session Date: Friday, July
19th
Session Time: 9:17am CEST
Presenter: Dr. Michael
Singer, Clinical Professor of Ophthalmology at the
University of Texas Health Science
Center
Dr. Singer will present end-of-study data from RESTORE, a
randomized controlled trial of Nanoscope's MCO optogenetic gene
therapy in patients with severe vision loss related to Retinitis
Pigmentosa (RP). MCO-treated subjects from RESTORE experienced
clinically meaningful improvements in best-corrected visual acuity
(BCVA) in a statistically significant manner. Dr. Singer will
discuss the importance and magnitude of the vision restoration
observed in MCO-treated patients from RESTORE in the context of the
natural history of declining vision in this patient population.
About Nanoscope Therapeutics Inc.
Nanoscope
Therapeutics is developing gene-agnostic, sight-restoring
optogenetic therapies for the millions of patients blinded by
inherited retinal diseases, for which no cure exists. The company's
lead asset, MCO-010, recently announced the 100-week data from the
RESTORE Phase 2b/3 multicenter,
randomized, double-masked, sham-controlled clinical trial in the
U.S. for retinitis pigmentosa (NCT04945772). The company has also
recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy
in patients with Stargardt disease (NCT05417126 ). MCO-010 has
received FDA fast-track designations and FDA orphan drug
designations for both retinitis pigmentosa and Stargardt disease.
Preclinical assets include non-viral laser-delivered MCO-020 gene
therapy for geographic atrophies secondary to AMD.
Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting-302192579.html
SOURCE Nanoscope Therapeutics